BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Income Statement
NASDAQ:BCRX - Nasdaq - US09058V1035 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 450.71M | 331.41M | 270.80M | 157.20M | 17.80M | |||
| Cost Of Goods | 12.48M | 4.66M | 6.60M | 7.30M | 1.70M | |||
| Gross Profit | 438.23M | 326.75M | 264.20M | 149.90M | 16.10M | |||
| Operating Expenses | 440.77M | 428.91M | 412.70M | 327.60M | 190.90M | |||
| Research and Development | 174.64M | 215.02M | 253.30M | 208.80M | 123.00M | |||
| Selling, General, and Administrative Expenses | 266.13M | 213.89M | 159.40M | 118.80M | 67.90M | |||
| Operating Income | -2.54M | -102.16M | -148.40M | -177.70M | -174.80M | |||
| Interest Income/Expense | -84.41M | -93.50M | -95.90M | -59.90M | -6.00M | |||
| Non Recurring Items | 0.00 | -30.57M | 0.00 | 55.80M | -2.00M | |||
| Income Before Taxes | -86.95M | -226.23M | -244.40M | -181.80M | -182.80M | |||
| Income Tax | 1.93M | 310.00K | 2.70M | 2.30M | N/A | |||
| Net Income | -88.88M | -226.54M | -247.10M | -184.10M | -182.80M | |||
| EBITDA | -1.30M | -100.51M | -146.96M | -176.92M | -174.05M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.43 | -1.18 | -1.33 | -1.03 | -1.09 | |||
| Non GAAP EPS | -0.43 | -0.99 | -1.33 | -1.03 | -1.08 | |||
| Statistics | ||||||||
| Gross Profit Margin | 97.23% | 98.59% | 97.56% | 95.36% | 90.45% | |||
| Profit Margin | -19.72% | -68.36% | -91.25% | -117.11% | -1026.97% | |||
| Operating Profit Margin | -0.56% | -30.83% | -54.80% | -113.04% | -982.02% | |||
All data in USD